Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 84

Results For "risk"

1377 News Found

Mandaviya reviews arrangements for screening and testing of international passengers
Policy | January 03, 2023

Mandaviya reviews arrangements for screening and testing of international passengers

Passengers arriving from 6 high-risk countries are now mandatorily required to upload their negative RT-PCR test


Eye-Q inaugurates its new facility in Yamunanagar
Healthcare | December 30, 2022

Eye-Q inaugurates its new facility in Yamunanagar

The new facility will be able to handle four times as many patients as the previous facility.


CDSCO and State Drugs Control Administration commence joint inspection of drug manufacturing units
Policy | December 28, 2022

CDSCO and State Drugs Control Administration commence joint inspection of drug manufacturing units

A committee of two Joint Drugs Controllers has been constituted at CDSCO to monitor the process of inspection, reporting, and subsequent action to ensure compliance to the Drugs & Cosmetics Act, 1940


Hetero's COVID-19 oral drug gets WHO prequalification
News | December 27, 2022

Hetero's COVID-19 oral drug gets WHO prequalification

WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission


Zydus receives final approval and 180 days shared exclusivity from USFDA for Selexipag Tablets
Drug Approval | December 23, 2022

Zydus receives final approval and 180 days shared exclusivity from USFDA for Selexipag Tablets

Selexipag tablet is indicated in adults for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization for PAH


Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer
Clinical Trials | December 22, 2022

Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe


Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers
Drug Approval | December 20, 2022

Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers

Positive opinions based on significant survival benefit


Torrent enters into co-marketing partnership with Boehringer Ingelheim India
News | December 15, 2022

Torrent enters into co-marketing partnership with Boehringer Ingelheim India

Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.


Hovione and GEA collaborate to advance continuous tableting
News | December 15, 2022

Hovione and GEA collaborate to advance continuous tableting

This partnership stemmed from a successful customer-supplier relationship spanning several years.


Evonik invests in US based biopharma company ‘Allay Therapeutics’
News | December 13, 2022

Evonik invests in US based biopharma company ‘Allay Therapeutics’

Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks